Key Highlights

  • The FDA requested additional data, including natural history study data, while talks on an open-label, single-arm BB-301 pivotal study continue.
  • Benitec reported a fiscal 2026 net loss of $45.5 million, or $0.98 per share, on operating expenses of $51.2 million.
  • Cash and cash equivalents stood at $180.0 million on June 30, 2026, compared with $97.7 million a year earlier.
  • Ernst & Young replaces Baker Tilly as auditor for fiscal 2027, and a prior material weakness was reported remediated.

Benitec (NASDAQ:BNTC) shares were trading near their 52-week low at USD 8.39 on October 19, 2026, up 3.45%. The gene therapy developer's latest update came on October 5, when it said the FDA was still discussing a pivotal design for its BB-301 candidate and wanted more data. It also reported a fiscal 2026 net loss and changed auditors in September.

BB-301 trial data and the FDA's request for more information

BB-301 is an AAV9-based gene therapy that silences a faulty gene and replaces it, aimed at swallowing difficulty in oculopharyngeal muscular dystrophy (OPMD). It is delivered to the pharyngeal muscle and holds orphan drug designation in the United States and Europe and Fast Track designation in the United States. The Phase 1b/2a study treated its first subject in November 2023.

All six Cohort 1 patients, who received the low dose, have completed 12 months of follow-up. Cohort 2, at the high dose, is fully enrolled, and its three patients were treated safely. Benitec reports clinically meaningful gains in patient-reported and X-ray-based swallowing measures and a favorable safety profile. Results are scheduled as a late-breaking poster at the ESGCT Annual Congress in Hamburg from October 27 to 30, 2026. The annual report cautions that early positive data may not predict later trial outcomes.

Benitec held a Type C meeting with the FDA in the third quarter of calendar 2026. In its October 5 release, the company said discussions on an open-label, single-arm pivotal study are ongoing and that the agency requested more data, including from Benitec's OPMD natural history study. The release did not disclose endpoints or sample size.

Fiscal 2026 loss, cash and funding

For the year ended June 30, 2026, operating expenses rose to $51.2 million from $41.8 million. Research and development expense was $23.4 million against $18.3 million, reflecting $6.3 million more share-based compensation, partly offset by lower contract manufacturing cost. General and administrative expense was $27.8 million against $23.4 million.

Net interest income of $5.6 million, up from $3.3 million, left a GAAP net loss of $45.5 million, or $0.98 per basic and diluted share, compared with $37.9 million, or $1.05.

Cash and cash equivalents were $180.0 million, against $97.7 million a year earlier. In November 2025, Benitec sold about $104 million of common stock in an underwritten offering and a concurrent registered direct offering. On September 14 it filed a new universal shelf registration covering up to $200 million of securities, which lists at-the-market offerings among possible sale methods without naming a sales agreement. Common shares outstanding were 34,882,726 on September 4. Management estimates cash will last at least twelve months after the annual report filing, and a risk factor warns that future auditor reports could include going-concern doubt.

Auditor change, milestones and risks ahead

On September 18, the audit committee dismissed Baker Tilly, the auditor since 2020, in what the company described as part of a governance review of the engagement. Baker Tilly's reports for fiscal 2025 and 2026 carried no adverse opinion and no going-concern modification, and Benitec reported no disagreements. The filing also notes a material weakness from the fiscal 2025 annual report, tied to the review of share-based compensation calculations, which the company said was remediated as of June 30, 2026. Ernst & Young was engaged for fiscal 2027, completing client acceptance on September 28 and signing an engagement letter on September 29.

Benitec plans to give the FDA the requested data in the coming weeks and expects to confirm the final pivotal design in the first quarter of 2027. It plans to begin pivotal enrollment in mid-2027 and describes its timelines as on track.